ES019: Anti-SIRPα/PD-L1 BiME® Molecule for Solid Tumor Immunotherapy
Tumor-associated macrophages are major component of immune cells in the tumor micro-environment (TME) that express an array of effector molecules leading to the inhibition of anti-tumor immune responses. SIRPα is a myeloid-lineage inhibitory receptor primarily expressed on phagocytic macrophages and DCs, which inhibits phagocytosis through engagement of its ligand CD47 expressed on tumors and normal tissues.
Leveraging our proprietary Bispecific Macrophage Engager (BiME®) technology, Elpiscience has developed ES019, a PD-L1/SIRPα bispecific antibody designed to simultaneously reactivate macrophages and T cells for tumor elimination. By targeting both tumor cells and immune cells, ES019 significantly enhances anti-tumor efficacy compared to monotherapy or combination treatments.